Chong Kun Dang Pharm Co (185750) · Earnings Release

AprilBio Co Ltd (397030) · Other

Final data from the Phase 1b clinical trial of APB-A1 for thyroid eye disease (TED) is scheduled to be presented at the ENDO conference on June 13, 2026. High importance is estimated due to the typical >10% price impact of clinical data, scheduled.

6/13/2026, 12:00:00 AM

LigaChem Biosciences Inc (141080) · Earnings Release

The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.

5/18/2026, 12:00:00 AM

Yuhan Corp (000100) · Earnings Release

Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.

4/30/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Earnings Release

Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.

4/30/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Other

Announced a strategic investment in US biotech 'General Proximity' to secure next-generation 'Induced Proximity' drug development technology, on April 30, 2026.

4/30/2026, 12:00:00 AM

SK Biopharmaceuticals Co Ltd (326030) · Other

An executive vice president is scheduled to announce a long-term revenue target for Cenobamate (Xcopri), aiming for $1 billion in U.S. sales by 2029 at the Bio Korea 2026 event on April 29, 2026; high importance is estimated as the $1B target is a critical valuation milestone for blockbuster status, scheduled.

4/29/2026, 12:00:00 AM